23andMe has entered a research collaboration with Mirador Therapeutics, a precision medicine company, to advance Mirador's immunology and inflammation-related disease therapy.

Under the partnership, Mirador will use a distinct set of de-identified genetic and phenotypic data from the 23andMe research database in association with its proprietary Mirador360 technology. The collaboration aims to enhance target validation and medicine precision to advance transformative precision therapies for chronic immune-influenced inflammatory and fibrotic ailments.

Mirador Therapeutics focuses on developing first-in-class therapeutics for immunology and inflammation (I&I). The company leverages its proprietary Mirador360 development engine, which analyzes patient molecular profiles to discover and validate genetic associations to immuno-fibrotic diseases. The platform identifies novel therapeutic targets and analyzes target-target interactions for potential combination therapies. The company's scope encompasses diseases of the gastrointestinal tract, lung, and skin. 

Analyst QuickTake: In March 2024 , Mirador Therapeutics raised USD 400 million in a seed funding round led by ARCH Venture Partners, including initial investments from OrbiMed and Fairmount. The funding was planned to be directed toward developing several therapeutic initiatives focused on immune-mediated inflammatory and fibrotic conditions. Through this partnership, it appears the company is moving ahead with its intentions.